Role of transforming growth factor-β1 in down-regulating TNF production by alveolar macrophages during asbestos-induced pulmonary fibrosis by Lemaire, Irma & Ouellet, Sophie
Research Paper
Mediators of Inflammation 5, 37-42 (1996)
ACTIVATION of alveolar macrophages (AM) for
tumour necrosis factor production is sup-
pressed initially during the inflammatory
response to flbrogerflc dusts. We investigated the
mechanisms involved in TNF suppression,
notably the role of other AM-derived mediators
including prostaglandin Ez (PGE2), transforming
growth factor-l (TGF-I), and interleukin 6 (IL-
6). The action of PGE2 and TGF-I, on AM was
different. At physiologically relevant doses (25-
00pg/ml), PGEz did not cause significant inhibi-
tion of Hpopolysaccharide CLps)-induced TNF
release by AM in vitro but stimulated IL-6 (up to
six fold), an inhibitor of AM-derived TNT. In
contrast, TGF-I (0.5-0ng/ml) inhibited both
LPS-induced TNT and IL-6 release by 0% but had
no effect on PGEz production by AM. To deter-
mine the respective contribution of these differ-
ent inhibitors in TNF suppression, AM from rats
exposed to flbrogenic asbestos for weeks were
treated with neutralizing antibody against TGF-I
or indomethacin, an inhibitor of PGE2 synthesis.
Treatment of rat AM with anti-TGF- but not
indomethacin, abrogated the observed TNT sup-
pression. These results suggest that an autocrine,
TGF-rdependent mechanism is involved in the
down-regulation of TNF production by rat AM
from animals with lung fibrosis.
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Introduction
Alveolar macrophages (AM) are an important
source of numerous cytokines and are a primary
cell type in chronic inflammatory reactions
induced by fibrogenic dusts.
2 It is likely that the
contribution of AM-derived cytokines plays an
important role in the maintenance and progres-
sion of pulmonary inflammation. Among these,
tumour necrosis factor-or (TNF) has attracted
much attention owing to a wide range of activ-
ities including fibroblast rowth-promoting and
growth-inhibiting activities. Together with other
cytokines, TNF is frequently found at sites of
inflammatory reactions and higher levels of TNF
messenger RNA were identified in lung tissue of
mice treated with silica5 and bleomycin.
6 With
regard to basal and LPS-stimulated TNF produc-
tion by AM, variable responses including stimula-
tion as well as inhibition or no change have been
reported in experimental silicosis.7-I0 Less infor-
mation is available concerning the contribution
of AM-derived TNF in asbestos-induced fibrosis.
In a previous study, we reported bidirectional
changes in LPS-stimulated TNF production by rat
AM exposed to fibrogenic asbestos.9 These
changes were characterized initially by a 50%
suppression of TNF and were associated with the
development of lung fibrosis but were absent in
resolving lung granuloma. TNF inhibition was
observed at a time when the bronchoalveolar cell
population was composed exclusively of macro-
phages, raising the possibility of a macrophage-
related inhibitory mechanism(s). Therefore, the
present work was undertaken to study the role
of macrophage-derived mediators, notably PGE2
and TGF-, in the observed TNF suppression.
We report here that down-regulation of AM-
derived TNF production was completely abro-
gated by TGF-I3 neutralization whereas indo-
methacin treatment had no effect. These results
suggest that TNF response in AM from animals
with lung fibrosis is inhibited in an autocrine
fashion by TGF-.
Materials and Methods
Induction of lung inflammation and fibrosis:
Male Wistar rats weighing 225-250g were pur-
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chased from Charles River Canada, Inc. (St Con- lected by centrifugation and frozen at -80C
stant, Quebec). These animals were derived from until assayed.
a pathogen-free colony, shipped behind filter
barriers, and housed in isolated temperature-con- Assays of TNF, IL-6 and TGF-flz: TNF activity was
trolled quarters in an animal isolator unit (Johns determined as described9 using the L929 routine
Scientific Inc., Toronto). Lung inflammation and fibroblast lysis assay. Serial dilutions of test
fibrosis were induced by intratracheal instillation supernatant were added to 4.5 x 104 L929 cells
of a preparation of chrysotile asbestos fibres as in the presence of actinomycin D (1 l.tg/ml)
described previously.9 UICC Canadian chrysotile (Boehringer Mannheim) and incubated for 18h
B asbestos fibres, (21% > 10gm)
) were in microtitre plates. The supematants were dis-
obtained from the National Research Institute for carded; the remaining adherent viable cells were
Occupational Diseases, Johannesburg, South stained with crystal violet (0.5% in 2% methanol)
Africa. Asbestos fibres were autoclaved for 45 and the absorbance of each well was read at
min and suspended in sterile phosphate-buffered 540nm using an automated Bio-Tek microplate
saline (PBS, pH 7.4) with a Dounce glass homo- reader (Mandel Scientific). Each assay was stan-
genizer (Fisher Scientific, Ottawa) before instilla- dardized with murine recombinant TNF
tion into the animals. Under anaesthesia, the (4 x 107U/mg, Genzyme) and TNF units were
trachea was exposed surgically and saline or calculated by probit analysis. TNF bioassay was
chwsotile B fibres were briskly injected through validated by using a rabbit antimurine TNF anti-
an 18-gauge needle. Two groups of seven rats body (Genzyme Corporation, Boston, MA) which
each, received respectively, a single intratracheal completely neutralizes the cytotoxicity of AM
injection of saline (control) or chrysotile B conditioned media.
(5 mg). The rats from each group were sacrificed IL-6 activity was measured with the standard
3 weeks after treatment and were analysed by B9 cells proliferation assay as described. B9
bronchoalveolar lavage (BAL), for BAL cell popu- cells (0.5 x 104) were incubated in 0.2ml of
lations and AM-derived TNF production. Histolo- Iscove’s Modified Dulbecco’s Medium (IMDM)
gical examination of lung sections stained with (Grand Island Biological Co.)supplemented with
haematoxylin-eosin or Masson’s trichrome 5% FBS and 5 x 10-5M 2-mercaptoethanol in
revealed the presence of fibrosis in the lungs of the presence of AM supematants at various dilu-
rats exposed to UICC chrysotile fibres.9 The tions. Tritiated thymidine (1 btCi/well) was added
lesions consisted of granulation tissue with fibro- after 66h of incubation and cultures were har-
blastic proliferation and collagen deposition and vested at 72h with a Skatron filtration device.
were localized predominantly in and around The sample dilution curve was related to a stan-
terminal bronchioles, dard curve generated with recombinant murine
IL-6 (Genzyme, 108U/mg) and IL-6 units were
Alveolar macropbage culture: Mveolar macro- calculated by probit analysis.
phages were obtained by bronchoalveolar lavage TGF-[31 activity was determined using the selec-
as described previously.9 Cells were counted in a tively sensitive MvlLu, mink lung connective tissue
haemocytometer chamber and viability (98- cell line (American Type Culture Collection, Rock-
100%) was determined by trypan blue exclusion, ville, MD: no. CCL-64) as described.
14 Cells
Differential analysis of lavage cells made from (2.5 x 104/well) were cultured for 4h in 96-well
cytocentrifuge smears (Shandon, 2.5 x 104 cells) flat-bottomed microtitre plates (Costar, Cam-
and stained with Wright-Giemsa indicated that bridge, MA) in MEM supplemented with 10%
the BAL cell population was essentially corn- foetal bovine serum (FBS) (Grand Island Biologi-
posed of macrophages (99% AM) in normal rats. cal Co., Grand Island, NY). AM culture super-
Similarly, in saline and asbestos-treated rats, the natants were then added in triplicate and
BAL cell population was 99% AM, the major dif- incubation was performed for 18 h. Cells were
ference between these two groups being a sig- pulsed for 6h with [H]thymidine (1.SgCi/well)
nificant increase in AM number in asbestos- (Dupont NEM). After washing with PBS, cells
treated animals (11 x 106 and 19 x 106 respec- were treated with trypsin-EDTA (0.5-0.03%) for
tively, for saline and asbestos groups). For deter- 40 min at room temperature and collected with a
mination of TNF, IL-6 and TGF-[3 bioactivities, Skatron harvester. Results were calculated based
AM (0.2 x 106) from normal rats and when indi- on the decrease of [H]thymidine incorporation
cated, from saline and asbestos-treated rats, were compared with natural human TGF-]3 standard
incubated in 0.2ml of DMEM supplemented with (Upstate Biotechnology Inc., NY) and data are
0.5% FBS for 18h at 37C in the presence and expressed as ng/ml. The specificity of the assay
absence of LPS (1 I.tg/ml) (Sigma Chemical Co., was demonstrated by using chicken anti-human
St Louis, MO). Culture supematants were col- TGF-[3 (R&D Systems)which inhibits the activity.
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Prostaglandin E2 determination: Prostaglandin
E2 (PGE2) was determined from AM supematants
using an ELISA kit (Cayman Chemical, Ann
Arbor, MI). The ELISA was a competitive acetyl-
cholinesterase-linked immunoassay and was
performed according to the manufacturer’s
instruction.
Neutralization and blocking experiments: AM
obtained from animals exposed to saline or UICC
chrysotile B asbestos for 3 weeks were incubated
as follows: AM (10*/ml) from each group were
incubated for 18h at 37C with LPS (1 l.tg/ml)
alone or in the presence of a purified turkey IgG
antibody (101g) to human transforming growth
factor-]3 (anti-TGF-J3)which displays neutraliz-
ing activity against rat TGF-[31 (Collaborative
Research, Bedford MA), turkey serum as a control
for anti-TGF-J3 or indomethacin (10-5 M)
(Sigma, St Louis, MO). AM culture supematants
were collected and frozen at -80C for TNF
measurement as described above.
Statistical analysis: Results were expressed as
mean values ___
S.E.M. Statistical significance of
differences between treated and control groups
were determined using a one-way analysis of var-
iance and Bonferrani test (Instat) (p < 0.05).
Results
PGE2 inhibited LPS-induced TNF release from
AM by 50% in a dose-dependent manner with
half-maximal effect observed at 25 Ig/ml
(Fig. 1A). This is much higher than the levels of
PGE2 produced by LPS activated AM (805 pg/ml)
(Table 1) indicating that physiological concentrao
tions of PGE2 are not sufficient to inhibit TNF
production by rat AM. In contrast, relatively small
concentrations of PGE2 (25-300 pg/ml) had a
direct stimulatory effect on spontaneous IL-6
release (7 U/ml), an inhibitor of TNF production
by rat AM. Up to six-fold stimulation (46 U/ml)
was obtained with 300pg/ml PGE2 (Fig. 1B). In
addition, LPS-stimulated IL-6 release (75U/ml)
was further increased two- to five-fold by PGE2
within the same concentration range.
On the other hand, TGF-[3 at concentrations
ranging between 0.5 and 50ng/ml caused sig-
nifican inhibition of LPS-induced TNF (Fig. 2A)
and It-6 (Fig. 2B) release by rat AM with
maximal inhibition (50%) obtained with 2.5-
5 ng/ml. In addition, TGF-]3 had a potent inhibi-
tory effect (54%) on LPS-induced PGE2 produc-
tion by AM (Table 1). Thus, TGF-]3 can directly
inhibit TNF production by AM whereas PGE2
may indirectly down-regulate TNF by stimulating
It-6.
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FIG. 1. AM (108/ml) from normal rat were incubated with
various concentrations of PGE2 as indicated, for 18 h in the pre-
sence and absence of LPS (1 Ig/ml). (A) TNF activity was mea-
sured in AM culture supernatants as described in Materials and
Methods. AM + LPS 134 U/ml or 3350 pg/ml. Values represent
mean -I- S.E.M. of three separate experiments. (B) IL-6 activity
was determined in AM culture supernatants as described in
Materials and Methods. Spontaneous IL-6 release (100%
response) was equivalent to 7 U/ml and PGE2 stimulatory effect
was expressed as percent of control. LPS-induced IL-6 release
(100% response) was equivalent to 75U/ml or 750pg/ml and
PGE2 stimulatory effect was expressed as percent of control.
Values represent mean -t- S.E.M. of four separate experiments.
Table 1. Effects of TGF-II on PGE2 production by AM
Treatment PGE2 (pg/ml)
AM 158.5 4- 54
AM + LPS (1 ig/ml) 805.2 4- 72
AM +TGF-II (2 ng/ml) 179.8 4- 37
AM + LPS+TGF-II (2 ng/ml) 378 4- 31
aAIveolar macrophages (10e/ml) were incubated as described in
Materials and Methods for 18 h in media alone or in the presence of LPS
or TGF-I or a combination of both. Prostaglandin concentrations were
determined in culture supernatants by ELISA. Data represent mean 4-
S.E.M. of three separate experiments.
To investigate which pathway(s) may be
involved in the down-regulation of AM-derived
TNF following asbestos exposure, AM obtained
from rats exposed to UICC chrysotile asbestos
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FIG. 2. AM (10S/ml) were incubated with increasing concentra-
tions of recombinant TGF-II for 18h in the presence and
absence of LPS (1 Ig/ml). (A) TNF activity was measured in AM
culture media as described in Materials and Methods.
AM + LPS 125 U/ml or 3125 pg/ml. Values represent mean ___
S.E.M. of three separate experiments. (B) IL-6 activity was mea-
sured in AM culture media as described in Materials and
Methods. AM + LPS-- 72 U/ml or 720 pg/ml. Values represent
mean 4- S.E.M. of four separate experiments.
for 3 weeks were incubated in the presence and
absence of anti-TGF-l known to neutralize rat
TGF-[ ,14 turkey serum as a control, and indo-
methacin, an inhibitor of PGE2 synthesis. Treat-
ment with anti-TGF- but not with turkey serum
or indomethacin abrogated the 50% suppression
of AM-derived TNF seen 3 weeks after asbestos
exposure (Fig. 3). At this time, AM culture media
from asbestos exposed rats contained levels of
TGF- (1.2ng/ml) sufficient for inhibition of
TNF release (Table 2).
Discussion
We have investigated the mechanisms involved
in TNF suppression during the development of
asbestos-induced fibrosis,9 at the macrophage
level. A variety of mediators are known to inhibit
5 TNF production from cells including IL-4, IL-
17 18 19 6, IL-10, PGE2 and TGF-I. Among these,
UlCC LPS
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FIG. 3. AM (10e/ml) from rats treated with saline or UlCC ch-
sotile B asbestos (5 rag) for 3 weeks were incubated for 18 h in
the presence of LPS (1 pg/ml) with either anti-TGF-l, turkey
serum or indomethacin. TNF activiW was determined in AM
culture supernatants as described in Materials and Methods.
Values represent mean S.E.M. of five animals per group. *Sig-
nificantly different from control at p < 0.05.
Table 2. Production of TGF-I by AM from control and asbestos
treated rats
Treatment TGF-I (ng/ml)
Saline 0.16 4- 0.03
Asbestos 1.2 -t- 0.1
aAIveolar macrophages (106/ml) from rats treated with saline or asbestos
for 3 weeks, were incubated for 18h. Culture supernatants were
collected and measured for TGF-I as described in Materials and
Methods. Values represent mean +__ S.E.M. of five animals per group.
IL-4 is produced by activated T-lymphocytes,
2 a
cell type which is not present in the broncho-
alveolar compartment of our inflammatory lung
model.2’ Because the alveolar macrophage
(AM) is a prominent feature of lung reactions to
asbestos,
2 our study focused on mediators pro-
duced by AM, notably PGE2, IL-6 and TGF-[. As
reported in other systems,m TGF-[ exerts sig-
nifican inhibitory effects on TNF release by acti-
vated rat AM, conditions that are consistent with
inflammatory states. TGF-I inhibits TNF release
within the concentration range produced by AM
suggesting that it could act in an autocrine
fashion to modulate TNF production in the pul-
monary microenvironment. In addition, TGF-[
inhibits LPS-induced PGE2 indicating that it sup-
presses TNF production through a PGE2-inde-
pendent pathway. This is consistent with
previous findings in peripheral blood mono-
nuclear cells19 and murine macrophage cell
lines.
2 Furthermore, TGF-] also inhibits IL-6
release from activated AM, ruling out the con-
tribution of IL-616 in mediating its suppressive
effect on TNF. Although TGF-fl has been repor-
ted to stimulate IL-6 production in fibroblasts,
22
chondrocytes and peripheral blood lympho-
cytes,
24 it has been shown to suppress IL-6 in
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bone marrow cells.25 Such differences are likely
to reflect cell-specific regulation of TNF by TGF-
[31. The molecular basis of TGF-[3 inhibitory
action on TNF production by rat AM is
unknown. As reported for human peripheral
blood mononuclear cells9 and murine peritoneal
macrophages,
26 TGF-[31 may block TNF by acting
post-transcriptionally in rat AM, possibly through
increased mRNA degradation or inhibition of
TNF mRNA translation.
26 In this respect, and
consistent with our observations, TGF-[3 appears
to act differently to PGE2 and IL-6, which both
have been shown to inhibit TNF transcrip-
tion.18’27 Further investigation would be neces-
sary to clarify this.
In contrast, relatively high non-physiological
concentrations of PGE2 (10-5M range) are
necessary for inhibition of TNF. This is in agree-
ment with previous studies which showed AM to
be less susceptible than monocytes to PGE2 inhi-
bition requiring much higher concentrations of
PGE2 (10-5-10-4M) for suppression of TNF.
28
Such high inhibitory levels of PGE2 could not be
achieved following LPS stimulation, indicating
that, under our experimental conditions, acti-
vated rat AM do not produce enough PGE2 to
interfere with TNF production. PGE2 on the
other hand, stimulates IL-6 release in rat AM. This
is in contrast to a recent report that PGE2 inhi-
bits LPS-induced release of IL-6 in murine perito-
neal macrophages.29 Such discrepancies are likely
due to differences in the experimental conditions
used, including cell preparations and concentra-
tions of PGE2. As mentioned earlier, AM are
fairly resistant to inhibition by PGE2 concentra-
tions (10-9M) used in the latter study.29
However, our results are in accordance with
other studies which demonstrate that augmenta-
tion of PGE2 correlates with an increase in IL-63
whereas inhibition of PGE2 blocks IL-6 produc-
tion.31’32 Interestingly, stimulation of IL-6 by PGEg
is observed within the physiological range of
concentrations produced by AM, raising the pos-
sibility that, under certain conditions, PGE2 may
contribute indirectly to TNF suppression by
increasing IL-6 levels. Our study, however, clearly
demonstrates that TNF suppression in AM from
fibrogenic rats is mediated through a TGF-[3-
dependent PGEz-independent mechanism(s).
This is based on our observations that neutraliz-
ing antibody to TGF-[31 blocks the observed 50%
inhibition of TNF whereas indomethacin treat-
ment has no effect. Furthermore, in contrast to
controls, AM from animals exposed to asbestos
produce amounts of TGF-I3 sufficient to cause
inhibition. The contribution of other inhibitors,
notably IL-6 and IL-10, cannot be completely
ruled out. However, our observations that PGE2
at physiological concentrations stimulate IL-6, do
not suggest a role for IL-6. In support of this,
previous work from this laboratory demonstrated
a lack of correlation between AM-derived IL-6
and TNF production following asbestos expo-
sure. Similarly, since PGE2 deactivation of mac-
rophages has recently been shown to be
mediated by IL-10,
29 our results are not con-
sistent with a role for IL-10. Further experiments
would be necessary to address these issues.
Collectively, our findings support a role for
AM-derived TGF-[3 in down-regulating AM-
derived TNF in an autocrine fashion. Our study
also provides further evidence for important
interactions between TGF-]31 and TNF during
inflammatory responses to injury. In this regard,
it is interesting to note that TGF-[31 and TNF
antagonize each other’s functions. Thus, TGF-[3
blocks numerous effects of TNF33 whereas TNF
inhibits the growth-promoting effects of TGF-
13
34 and wound healing.35 This is in agreement
with recent work which demonstrated that mRNA
for TNF was greatly increased in TGF-[3 knock-
out animals36 and that deficient expression of
TGF-I was correlated with dysregulated produc-
tion of TNF and lethal dysfunction of the inflam-
matory system. Since TGF-3 exerts numerous
biological activities that are directly relevant to
tissue repair,
3v TGF-[3-induced suppression of
TNF may be a requisite step for appropriate
repair response following injury.
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